Intensity-Modulated Radiotherapy Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

What this Trial Is About

Researchers are evaluating the effectiveness and safety of intensity-modulated radiotherapy (IMRT) alone in patients diagnosed with stage IB nasopharyngeal carcinoma (NPC) who do not have high-risk features. This observational study focuses on determining how well this targeted radiation therapy works for this specific group of patients. The study is sponsored by Qiaojuan Guo and aims to provide important information about treatment outcomes for this type of cancer. The study involves 169 patients who will receive definitive IMRT treatment alone. Participants will not receive additional therapies such as chemotherapy or surgery for their primary tumor or metastatic nodes. The radiation is delivered using advanced techniques designed to target the tumor while limiting exposure to surrounding healthy tissues. There are no separate treatment arms; all patients undergo the same radiotherapy approach. During the study, researchers will monitor participants regularly to assess relapse-free survival over three years as the primary outcome. Secondary outcomes include locoregional relapse-free survival, distant metastasis-free survival, overall survival, radiation safety, and quality of life assessments using standard questionnaires at multiple time points up to five years. Safety evaluations occur at inclusion and at 3, 6, 12, 24, 36, and 60 months, allowing thorough monitoring of treatment effects and patient well-being throughout the study period.

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features